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Abstract 
The use of polyADPribose polymerase inhibitors in cancer treatment provides a unique opportunity to 
target DNA repair processes in cancer cells while leaving normal tissue intact. The PARP-1 enzyme 
repairs DNA single strand breaks (SSB). Therefore PARP-1 inhibition in BRCA1 negative cancers results 
in the formation of cytotoxic DNA double strand breaks (DSB) causing synthetic lethality. The use of 
PARP1 inhibitors is gaining momentum in the treatment of a variety of tumours with BRCA1 
involvement including breast, ovarian, pancreatic and prostate cancer.  
Our previous work showed that the PARP-1 inhibitor Olaparib causes both hypersensitivity of BRCA1+/– 
cells following exposure to gamma radiation due to the persistence of DNA strand breaks in cells, 
measured by the DNA damage biomarker γ-H2AX. Therefore dual treatment of cancers with 
radiotherapy and PARP1 inhibition may lead to cases of increased normal tissue toxicity in cancer 
patients.  
In this study we exposed two normal lymphoblastoid cell lines and three heterozygous BRCA1 
lymphoblastoid cell lines to the PARP-1 inhibitor Olaparib and gamma radiation and after measured 
BRCA1 protein expression and apoptosis levels following treatment. BRCA1 protein foci analysis was 
performed on cells exposed to 2 Gy radiation in the presence or absence of 5 μM Olaparib. Using 
immunofluorescence and imaging flow cytometry, foci were measured in untreated cells and at 0.5, 3, 5 
and 24 hours post-irradiation. Exposing normal and BRCA1+/- cells to Olaparib followed by gamma 
radiation results in a dramatic change in BRCA1 protein foci expression, with a significant reduction in 
BRCA1 protein expression observed in the heterozygote cells, together with an increase in apoptosis 
levels in these cells.  
In conclusion, combining PARP1 inhibitors with radiotherapy in treating of BRCA1-related cancers has 
clinical relevance, however this study and our previous publications serve to highlight the potential 
problems of increased side effects in these scenarios. 
Introduction 
The poly(ADP-ribose) polymerase (PARP) 
family of enzymes are involved in a number of 
cellular processes, including DNA transcription, 
genome maintenance (including DNA damage 
response and repair), cell cycle regulation and cell 
death. The PARP-1 enzyme, the most abundant and 
ubiquitous of these enzymes [1], identifies and repairs 
DNA single strand breaks (SSB) primarily via the base 
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excision repair (BER) mechanism. Inhibition of 
PARP-1 results in DNA double strand breaks (DSB) 
forming from SSB during DNA replication [2].  
The first molecular inhibitors of PARP, 
synthesised over 40 years ago, were nicotinamide 
analogues such as the benzamides e.g. 
3-aminobenzamide. Further research and 
development yielded more potent PARP inhibitors 
that have recently entered the clinical setting e.g. 
Olaparib [3]. Facilitating the accumulation of DNA 
DSB in tumour cells by chemically inhibiting the 
PARP-1 enzyme has an important role in cancer 
treatment, particularly in treating cancers with 
mutations in BReast CAncer susceptibility genes 1 
and 2 (BRCA1 and BRCA2, respectively) [4].  
BRCA1 and BRCA2 are tumour suppressor genes 
involved in many cellular processes, especially DNA 
repair and transcriptional regulation in response to 
DNA damage [5]. Such DNA damage, particularly 
from the ionising radiation used in clinical 
radiotherapy, is repaired using one of two separate 
pathways, non-homologous end joining (NHEJ) and 
homologous recombination (HR). Whilst NHEJ, 
although error prone, repairs DNA DSB in all stages 
of the cell cycle, HR repair is the dominant repair 
mechanism in cycling (G2 and S stage) cells [6]. 
Investigations revealed that both BRCA1 and BRCA2 
proteins are active in HR; BRCA1 is a signal mediator, 
and BRCA2 initiates repair by recruiting Rad51 to 
DSB [7].  
PARP1 knockout mice (PARP−/−) are both viable 
and fertile, despite exhibiting defective DNA SSB 
repair, possibly because they also exhibit elevated 
levels of error-free HR [8]. In the majority of cell lines, 
treatment with a PARP inhibitor at concentrations 
that inhibit PARP activity does not automatically 
initiate cell death. However, breast cancer cells with 
homozygous mutations in either BRCA1 or BRCA2 
exhibited extreme sensitivity to PARP inhibitors [8-9]. 
This is an example of synthetic lethality, where the 
simultaneous loss of two genes or proteins (in this 
case PARP-1 and BRCA) causes cell death that would 
not occur if singular gene or protein function was lost 
[10]. BRCA1 interacts with a wide range of DNA 
repair proteins, for example by directing the 
MRE11/RAD50/NBS1 complex to DSB sites, where it 
plays a role in DNA strand break resection. Therefore 
cells with homozygous mutations in BRCA1 are likely 
to have greatly decreased DNA DSB repair capacity 
[11]. This, together with increased DSB formation 
from PARP-1 inhibition, produces an accumulation of 
DSB that is lethal to the cell.  
Fractionated radiotherapy is a standard 
treatment method for many locally advanced cancers, 
including breast cancer. Side effects, termed normal 
tissue toxicity (NTT), are reported in 15-20% patients 
undergoing such treatment, and in severe cases can 
limit the treatment effectiveness [12]. NTT has been 
standardised into scales for all tissue types [13-14]. It 
has also been observed that a small minority of 
patients exhibit side effects that are so severe as to fall 
outside of the established NTT scales – these 
individuals are referred to as ‘over-reactors’. 
Frequently over-reactors possess one or more 
inherited genetic defects in the repair of DNA double 
strand breaks (DSB), for example Ataxia 
Telangiectasia (A-T) [15], and Severe Combined 
Immunodeficiency with Sensitivity to Ionising 
Radiation (RS-SCID) [16]. We have previously 
reported a clinical case of patient death resulting from 
radiotherapy-induced neurological trauma. The 
patient was found to be carrying an inactivating 
mutation in the DNA-PKcs gene (which is central to 
DSB repair), resulting in extreme cellular and clinical 
radiosensitivity [17].  
The fact that the BRCA1 and BRCA2 proteins are 
central to proficient DNA DSB repair by either NHEJ 
or HR produces the possibility that individuals 
carrying mutations in either of these genes might 
represent a cohort of patients in which 
radiotherapy-induced NTT might be over and above 
the normal range expected. Indeed cellular clonogenic 
assays in cells derived from BRCA1 and BRCA2 
heterozygotes reveal elevated radiosensitivity and 
chromosome aberrations when compared to cells 
derived from normal individuals, which is suggestive 
of a haplo-insufficient phenotype [18]. However, 
clinical evidence suggests that heterozygotes for both 
BRCA1 and BRCA2 do not experience abnormally 
severe NTT [19]. 
Our previous studies determined that 
lymphoblastoid cells heterozygous for BRCA1 
exhibited hypersensitivity (in the form of decreased 
cell survival) when exposed to a combination of the 
PARP inhibitor Olaparib and gamma radiation [20]. 
This correlated with prolonged persistence of γ-H2AX 
foci (indicative of DNA DSB) within the same cells 
[21]. Whilst this therapeutic combination is 
undoubtedly promising effectiveness when treating 
tumours homozygous for BRCA1 mutations in 
pre-clinical trials [22], we cautioned that these 
patients may also experience increased NTT levels, 
caused by DNA damage and subsequent apoptosis of 
cells in normal tissue that are heterozygous for BRCA1 
mutations.  
We now report from an in-depth investigation 
using imaging flow cytometry that this 
hypersensitivity is due to reduced levels of BRCA1 
protein in the cell, specifically the nucleus, and 
enhanced apoptosis of the cells.  
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Materials and methods 
Cell lines 
Human B lymphocytes which had been 
immortalised using the Epstein-Barr virus were 
purchased from Coriell Cell Repositories (Camden, 
New Jersey, USA). Details of the cell lines are shown 
in Table 1. Cell lines "BRCA1" were heterozygotes for 
mutations in the BRCA1 gene. The nature of these 
mutations is also detailed in Table 1. 
 
Table 1. Description of B-Lymphoblastoid cell lines used in study 
Cell Line Type Details of BRCA Gene Mutation 
GM00893 Normal None 
GM05423 Normal None 
GM13705 BRCA1 4-base pair deletion in exon 11 = truncated 
protein.  
GM14090 BRCA1 2-base pair deletion in exon 3 = truncated 
protein. 
GM16105 BRCA1 Base substitution in intron 8. 
 
Cell culture 
The cell lines were initially established in T25 cell 
culture flasks (Sarstedt, Leicester, UK) in RPMI 1640 
culture medium (Labtech International Ltd, East 
Sussex, UK) supplemented with 20% foetal bovine 
serum (Scientific Laboratory Supplies, Yorkshire, 
UK), 2.0 mM L-Glutamine (Labtech International 
Ltd.), 100 Uml−1 Penicillin and 100 µgml−1 
Streptomycin (Labtech International Ltd). After two 
days cell lines were transferred to T75 flasks for 
ongoing culture. Cells were routinely incubated at 
37°C in a humidified atmosphere of 5% CO2 in air.  
Cell concentration values (number of cells per ml 
cell suspension) and viability values (% live 
cells/dead cells) were determined as required using a 
"Countess™" automated cell counter based upon the 
method of trypan blue exclusion (Invitrogen, 
Renfrewshire, UK). Cell cultures were maintained 
at approximately 2 × 105 viable cells/ml; for 
experiments this was increased to approximately 1 × 
106 viable cells/ml. Cell lines were used over a 
restricted range of ten passages, during which cell 
viability was not less than 80%.  
Exposure to radiation and the PARP inhibitor 
Olaparib 
Prior to irradiation, the cell suspension of each 
cell line was divided in half; one suspension was 
incubated for 1 hour in 5.0 µM Olaparib (LC 
Laboratories Inc., Woburn, Massachusetts, USA) 
whilst the other remained in RPMI-1640 medium, 
supplemented as above. The Olaparib concentration 
used (5.0 µM) was found from previous work to be 
the maximum concentration that did not significantly 
decrease cell survival [20]. One aliquot of 10 ml from 
each cell suspension was retained as an un-irradiated 
control; the remaining cell suspensions were 
irradiated with 2 Gy gamma radiation from a 60Cobalt 
source (Puridec Technologies, Oxfordshire, UK) sited 
at a distance of 25 cm with a dose rate of 0.7 Gy per 
minute. 
Cell fixation 
Irradiated cells were fixed at 30 minutes, 3 hours, 
5 hours and 24 hours post-irradiation, with two 
samples reserved as compensation samples fixed at 
the 30 minute time point where the level of DNA 
damage and therefore fluorescence was expected to 
be at the maximal level. The un-irradiated control 
cells were fixed using the same method. Cells were 
pelleted by centrifugation at 1500 rpm for 5 minutes at 
room temperature and the complete medium 
discarded, washed with phosphate buffered saline 
(PBS) (Severn Biotech Ltd, Worcestershire, UK) and 
fixed in ice-cold 50:50 (V:V) methanol:acetone. 
Samples were stored at −20°C until submission to the 
immunocytochemistry stage [21].  
Immunocytochemistry 
Cells were re-hydrated by washing in PBS 
(Severn Biotech Ltd) at 4°C then incubated with gentle 
agitation for 5 minutes at room temperature in 
permeabilisation buffer consisting of 0.5% Triton™ 
X-100 (Sigma-Aldrich, Dorset, UK) in PBS. Cells were 
subsequently incubated with gentle agitation for 1 
hour at room temperature in blocking buffer 
consisting of 5.0% rabbit serum (Labtech International 
Ltd), with 0.1% Triton™ X-100 in PBS. After removal 
of the blocking buffer the cells were incubated with 
gentle agitation overnight at 4°C in primary antibody 
solution. The primary antibody solution consisted of 
an anti-BRCA1 mouse monoclonal antibody, clone 
number MS110 (Abcam, Cambridge, UK) diluted 1 in 
2000 in blocking buffer. Wash buffer, consisting of 
0.1% Triton™ X-100 in PBS, was used in two 
sequential steps to remove excess primary antibody. 
A secondary antibody solution, consisting of an Alexa 
Fluor®488 rabbit anti-mouse IgG antibody 
(Invitrogen) diluted 1 in 1000 in blocking buffer, was 
added to each sample, except the DRAQ5™ 
compensation samples. The cells were incubated with 
gentle agitation for 2 hours at room temperature, and 
excess secondary antibody was removed by washing 
twice with wash buffer. The cells were re-suspended 
in 100 µl Accumax™ solution (Labtech International 
Ltd), and left overnight at 4°C, but with no agitation. 
1.0 µl of 5 mM DRAQ5™ solution (Biostatus Limited, 
Leicestershire, UK) was added to each sample, except 
the AlexaFluor®488 compensation samples, and the 
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samples submitted for analysis by imaging flow 
cytometry.  
Imaging flow cytometry 
Imaging flow cytometry was undertaken using 
the ImagestreamX Mark II system equipped with 
Inspire™ data acquisition software (Amnis Inc., 
Seattle, Washington, USA). This system captures 
images of each cell in flow using a maximum of six 
optical channels. Images of 10,000 cells were obtained 
on channel 1 for brightfield (BF); on channel 2 for 
Alexa Fluor®488 (AF) – this green stain indicating the 
presence of BRCA1 protein; and on channel 5 for 
DRAQ5™ (D5) – a red stain identifying the cell 
nucleus. Application of gating in real time permitted 
the capture of single cell images.  
Image compensation 
Image compensation is described in detail 
previously [21]. In brief, it was performed on the cell 
populations fixed 30 minutes post-irradiation where 
BRCA1 protein expression, and hence staining 
intensity, was highest. Images of cells stained with 
either antibody or DRAQ5™ were collected with the 
488 nm laser only and were used to generate the 
compensation matrix. The software compensation 
wizard generated a table of coefficients whereby 
detected light displayed by each image was placed 
into the proper channel (channel 2 for antibody 
staining and channel 5 for DRAQ5) on a pixel-by-pixel 
basis. The coefficients were normalized to 1 and each 
coefficient represented the leakage of fluorescent 
signal into juxtaposed channels. Calculated 
compensation values were applied to all subsequent 
analyses as appropriate.  
Analysis of cell images - calculation of foci 
number 
Foci indicating the presence of the BRCA1 
protein were quantified in approximately 10,000 
images of cells per time point captured using the 
Inspire™ imaging flow cytometry software. Foci were 
quantified in a similar manner as described 
previously [23], with the spot counting wizard in the 
Ideas™ software permitting simplified foci 
quantitation. The wizard consists of sequential steps 
that identified and gated from all captured images 
those single cells that were in optical focus. Next, 
images of fifty cells from this population with varying 
numbers of clearly defined foci were selected to create 
a truth population. Images from the truth population 
were used to produce a mask that identified only 
those foci located within the cell nuclei of each image. 
The finalised truth population was then saved as a 
template and applied to quantitate foci present in all 
acquired cell images.  
Analysis of apoptotic cell images 
Significant changes in nuclear morphology are 
associated with apoptosis which include nuclear 
fragmentation and condensation of the DNA. Cellular 
morphological changes associated with apoptosis 
makes possible the automated identification of 
apoptotic cells. By measuring the area and the 
intensities of the brightest portions of the nuclear 
image, the bright, punctate nuclear imagery of 
apoptotic cells can be distinguished from the evenly 
stained nuclear imagery of a normal, healthy nucleus. 
An analysis wizard which compares nuclear 
bright detail intensity and nuclear area effectively 
distinguishes apoptotic cells from healthy cells with a 
normal nuclear and cytoplasmic structure. 
Statistical analysis 
Data generated from the application of the 
Ideas™ software was further analysed using the data 
analysis programme in Microsoft Excel. A one way 
analysis of variance test was utilised to determine if 
there were significant differences in foci number 
within the cell populations at different time points 
after Olaparib and gamma radiation exposure. These 
populations consisted of cells treated or untreated 
with Olaparib prior to being irradiated and then fixed 
at specific time points post-irradiation. 
Results 
Quantitation of BRCA1 protein foci in normal 
and BRCA1+/- lymphoblastoid cells following 
gamma radiation exposure  
Initial analysis was conducted to compare the 
number of BRCA1 protein foci in the nuclei of 
lymphoblastoid cells derived from two normal 
individuals (GM00893 and GM05423) with three lines 
derived from BRCA1+/- patients (GM13705, GM14090 
and GM16105) over a period of 24 hours following the 
induction of DNA damage by exposure to 2 Gy 
gamma radiation. In Figure 1 the mean number of 
BRCA1 foci for the two normal cell lines and the three 
BRCA1+/- lines are plotted in a bar chart at each time 
point following exposure. Using a one way ANOVA 
test to determine differences in the mean number of 
foci at each time point we determined that there are 
significantly fewer foci in the BRCA1+/- cell lines when 
compared to normal cells (P = 0.0375). 
Figure 2 examines the number of BRCA1 foci in 
each of the three BRCA1+/- cell lines in comparison to 
the two normal cell lines. In each of the three BRCA1 
heterozygotic cell lines we unsurprisingly observed 
fewer BRCA1 foci when compare to cells derived 
from normal individuals. This reduction of foci is 
most pronounced in the GM16105 BRCA1+/- line 
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where it can be observed that at all time points here 
are significantly fewer foci compared to normal 
(ANOVA: P = 3.14 x 10-6). Additionally in the two 
other BRCA1+/- lines (GM13705 and GM14090) we 
observe a significant reduction in foci when compared 
to normal cells (ANOVA P = 0.000114 and P = 0.006 
respectively). 
BRCA1 protein expression in normal and 
BRCA1+/- cells following exposure to Olaparib 
and gamma radiation 
Having established the base level of BRCA1 
protein/foci expression in the panel of cell lines 
following radiation exposure we wished to determine 
if the intracellular levels of BRCA1 protein were 
altered by the prior incubation with the PARP-1 
inhibitor Olaparib. This experiment was driven by the 
fact that in previous observations [20] we observed 
hypersensitivity to ionising radiation in BRCA1 
heterozygote cells after Olaparib treatment. Figure 3 
depicts the mean levels of BRCA1 protein foci in two 
normal lymphoblastoid cell lines after 2 Gy gamma 
radiation in the absence or presence of Olaparib. In 
addition we show the mean number of BRCA1 foci in 
three BRCA1+/- cell lines after radiation 
exposure with and without Olaparib 
treatment. We observed that in all cell 
lines there is a reduction of BRCA1 
protein foci when the cells are 
pre-treated with a non-cytotoxic dose of 
5 µM Olaparib. In the normal cells there 
is minor but significant reduction in the 
number of BRCA1 protein foci induced 
by Olaparib incubation prior to gamma 
irradiation when compared to normal 
cells irradiated without PARP1 
inhibition by Olaparib (ANOVA, P = 
0.031). In addition in the BRCA1+/- cell 
lines the reduction on BRCA1 protein 
foci is more pronounced with on 
average two fewer BRCA1 protein foci 
per cell (ANOVA, P = 0.00051). The most 
dramatic effect of BRCA1 protein foci 
expression can be observed when 
normal cells are compared to BRCA1+/- 
cells after Olaparib exposure. A 
significant reduction in foci is seen in the 
heterozygote cells where on average 
there are 3 fewer foci per cell (ANOVA, 
P = 8.22 x 10-6). 
To demonstrate that appearance of 
BRCA1 protein foci as derived in 
imaging flow cytometry, representative 
examples of multispectral images of cells 
with increasing foci are shown in 
Figure 4. 
Increased apoptosis in BRCA1 
heterozygote lymphoblastoid cells 
following Olaparib and gamma 
radiation exposure 
In our previous investigations 
[20-21] we observed increased 
radiosensitivity in BRCA1 heterozygotic 
cells when compared to normal cells 
following Olaparib exposure and that 
this elevated sensitivity was due to a 
 
 
Figure 1 shows the number of BRCA1 protein foci in the nuclei of lymphoblastoid cells derived from 
two normal individuals (GM00893 and GM05423) and from three BRCA1 heterozygote patients 
(GM14090, GM14090, GM16105). Bar charts are shown as normal or BRCA1 mutated (+/-) where 
the data form each cell line is combined. Error bars depict standard error of the mean of two 
independent experiments where images of at least 10,000 cells were captured and analysed. 
 
Figure 2 shows the number of BRCA1 protein foci in two normal lymphoblastoid cell lines and three 
cell lines derived from BRCA1 heterozygotes as indicated in the figure. Error bars depict standard 
error of the mean of two independent experiments where 10,000 cell images where captured in each 
experiment. 
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reduction in the repair of DNA DSB following 
radiation exposure. In order to determine the 
mechanism of cell death responsible for this enhanced 
sensitivity we examined the levels of apoptosis 
induction using the analysis wizard in the Ideas™ 
software package.  
 In Figure 5 it can be observed 
in both the normal and BRCA1+/- 
cells we observed an increase in 
apoptosis in those cultures that 
were treated with Olaparib and 
gamma radiation compared to 
those cultures that received no 
apriori Olaparib treatment. In the 
normal cells however, this increase 
in the overall levels of apoptosis 
was not significant (ANOVA, P = 
0.731). This increase in apoptosis 
was most pronounced in the 
BRCA1+/- cultures where apoptosis 
increased to between 40-50% in all 
BRCA1+/- cell lines over a 24 hour 
time period after Olaparib 
exposure. In normal 
lymphoblastoid cell lines and 
non-Olaparib treated BRCA1+/- 
lymphoblastoid cell lines apoptosis 
ranged between 10-25% (ANOVA, 
P = 2.54 x 10-5). 
The levels of apoptosis in the 
normal and BRCA1+/- cells are 
shown in Figure 5 and are 
presented as percentages of 
apoptotic cells within the entire 
culture of cells.  
 Figure 6 is a representative 
example of a dot plot from the 
Ideas™ software demonstrating the 
identification of apoptotic cells 
using the Ideas™ wizard tool. The 
region identified as non-apoptotic 
is shown together with a 
representative cell within the image 
and the apoptotic cell region is 
shown together with an image of a 
cell undergoing apoptosis with 
extensive membrane blebbing 
characteristic of apoptotic cells. 
Conclusion 
 Our previous studies have 
demonstrated that lymphoblastoid 
cells derived from BRCA1 
heterozygotes, when compared to 
normal or BRCA2 heterozygote 
cells, are hypersensitive to gamma 
radiation if pre-treated with the 
PARP1 inhibitor Olaparib [20-21]. 
 
 
Figure 3 shows the number of BRCA1 protein foci in two normal lymphoblastoid cell lines (GM00893 and 
GM05423) and three BRCA1 heterozygote cell lines (GM14090, GM14090, GM16105). Foci numbers are 
given for each cell type following radiation exposure with or without prior Olaparib treatment. Error bars 
depict standard error of the mean of two independent experiments where 10,000 cell images where 
captured in each experiment. 
 
Figure 4 show multispectral images of cells where channel 1 shows a brightfield image; channel 2, BRCA1 
protein foci and channel 3 shows a nuclear image of each cell. 
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In this study we extend these findings and show that 
there is reduced BRCA1 protein in heterozygote cells 
from BRCA1 carriers and that BRCA1 protein levels 
are further reduced by Olaparib exposure. Moreover, 
we show that the increased hypersensitivity in BRCA1 
carrier cells is due to elevated apoptosis after Olaparib 
and radiation exposure. 
Poly(ADP-ribose) polymerase 1 (PARP1) is an 
important enzyme involved in the repair of DNA 
single strand breaks. Therapeutic inhibition of PARP1 
in a BRCA1-/- tumour leads to the formation of a 
potentially cytotoxic DNA double strand break at 
stalled replication forks resulting in synthetic lethality 
and tumour cell kill [10]. Therefore the clinical use of 
PARP1 inhibition in the treatment of BRCA1 negative 
breast, ovarian, pancreatic and prostate cancers is 
gaining momentum as a viable 
and effective treatment option 
[4].  
While such cancers lend 
themselves to therapeutic 
inhibition of PARP1, more 
typical treatments utilise 
traditional cytotoxic 
radiotherapy and chemotherapy 
approaches [24]. Our research 
group has been interested in the 
factors controlling normal tissue 
toxicity (NTT) as a result of 
clinical radiotherapy. Some 50% 
of all cancer patients, 
irrespective of the histological 
cancer type, will receive 
radiotherapy (teletherapy or 
internal brachytherapy) as a part 
of their treatment [25] and 
evidence dictates that some 20% 
of all patients will experience 
side effects to a greater or lesser 
level in the form of NTT [26]. 
NTT has been classified 
according to tissue type and 
symptoms (acute or chronic) 
into standardised scales of NTT. 
These include the Radiation 
Therapy Oncology Group/ 
European Organisation for 
Research and Treatment of 
Cancer scale (RTOG/EORTC) 
and the Late Effects Normal 
Tissue Task Force subjective, 
objective, management and 
analytic (LENT/SOMA) scale 
[27]. While the level of NTT in 
the majority of radiotherapy can 
be predicted, some individuals 
experience NTT which is so 
severe that it falls outside the 
normal standardised scale of 
responses and such patients are 
regarded as “over-reactors”. In 
such cases treatment with 
normal therapeutic doses of 
 
 
Figure 5 shows the number of apoptotic cells in two normal and three BRCA1 heterozygotes lymphoblastoid cell 
lines. Error bars represent standard error of the mean of two independent experiments where 10,000 cell images 
were captured. 
 
Figure 6 shows a prototypical imaging flow cytometric dot plot of apoptotic and non-apoptotic cells. Each dot 
within the graph represents an individual cell and apoptotic cells are distinguished from non-apoptotic cells by 
nuclear area and brightfield image contrast. 
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radiotherapy evoke dramatic NTT sequelae that can 
lead to death. Individuals with inherited defects in 
DNA repair genes such as the ataxia telangiectasia 
mutated gene (ATM) where a defect in cell cycle 
checkpoint control leads to extreme 
radiotherapy-induced NTT [15] would constitute an 
over-reactor. In addition, our group has demonstrated 
that a patient who over-reacted to radiotherapy, 
resulting in death, harboured a mutation in the 
DNA-PKcs gene, which is central to efficient 
non-homologous end joining (NHEJ) repair of DNA 
strand breaks [17]. Therefore while there are many 
factors which may dictate NTT in a radiotherapy 
patient, it is undisputed that occult defects and 
deficiencies in the repair of DNA strand break 
induced by radiotherapy are central to NTT [26-28]. 
Both the BRCA1 and BRCA2 genes are central to 
the repair of DNA DSB by both non homologous end 
joining (NHEJ) and homologous recombination (HR) 
and consequently the DNA repair function of these 
proteins may render patients susceptible to abnormal 
levels of NTT following radiotherapy if the patient is 
heterozygous for these genes in non-cancer normal 
tissue. Conversely it may be assumed that since it is 
only the tumour that is fully BRCA1-/- or BRCA2-/- 
while the patient is monoallelic for these genes then 
NTT should not be expected. However, the 
phenomenon of haploinsufficiency of DNA repair 
genes leading to increased NTT has been 
demonstrated in some scenarios. For example in 
Li-Fraumeni patients with an inherited mutation in 
the P53 gene, increased cancer incidence and 
sensitivity to DNA damaging agents at the cellular 
and clinical level can be observed [29]. Moreover we 
demonstrated in a patient that experienced extreme 
cellular radiation hypersensitivity and NTT resulting 
in death, a monoallelic mutation in the DNA-PKcs 
DNA repair gene was responsible. Correspondingly, 
we previously hypothesised that BRCA1+/- individuals 
receiving radiotherapy for BRCA1-/- cancer might 
experience abnormally high levels of NTT. Moreover, 
this might be exacerbated in combinations of 
treatment where radiotherapy and PARP1 inhibitors 
are used. While there is conflicting evidence that 
patients who are BRCA1+/- experience NTT, we have 
demonstrated that lymphoblastoid cells derived from 
BRCA1+/- heterozygotes are hypersensitive to 
radiotherapy if PARP1 has been inhibited by prior 
exposure to the inhibitor Olaparib [20] and that this 
sensitivity was due to a failure to efficiently repair 
DNA DSB evidenced by a retention of γ-H2AX foci in 
the nuclei of cells following 2 Gy gamma irradiation 
and Olaparib exposure [21]. 
To understand the mechanism of sensitivity in 
the lymphoblastoid cells derived from BRCA1+/- 
patients, we used imaging flow cytometry to 
investigate the effects of Olaparib exposure on BRCA1 
protein levels and evaluated the mechanism of cell kill 
underlying the observed hypersensitivity. Imaging 
flow cytometry is a novel technique combining 
microscopic image acquisition of cells in flow across 
multiple channels including bright, darkfield and 
fluorescence image capture. We have extensive 
experience in this technique and have developed 
protocols for the determination of DNA damage 
[26-30], apoptosis in human cells [31] and 
identification of circulating tumour cells (Al-Ali et al., 
2017 paper submitted). 
In this study we were able to demonstrate that in 
lymphoblastic cells derived from BRCA1 
heterozygotes there were fewer BRCA1 protein foci in 
the nuclei of cells when compared to cells derived 
from normal individuals. Prima facie, such an 
observation would be expected and support the 
notion of haploinsufficiency observed with many 
DNA repair genes. However, previous investigations 
have demonstrated that reduced BRCA1 protein in 
heterozygotic cells is very much mutation specific, 
[e.g. 32] which demonstrated that carriers with 
mutations in exon 11 had reduced BRCA1 mRNA 
transcripts compared to other carrier mutations. In the 
three BRCA1+/- cell lines used here, GM13705 and 
GM14090 both have base pair deletions (exon 11 and 3 
respectively) leading to a truncated protein while 
GM16105 harbours a missense mutation in exon 5. We 
observed the most pronounced reduction in protein 
levels in the GM16105 cell line compared to those 
harbouring base pair deletions.  
A second fundamental finding from this 
investigation was the significant reduction in BRCA1 
protein foci levels when cells were treated with 
Olaparib prior to 2 Gy gamma radiation exposure. A 
slight but significant reduction was seen in cells 
derived from two normal individuals when Olaparib 
treatment occurred prior to radiation exposure but 
this was more pronounced in cells carrying a BRCA1 
mutation. While this observation would provide a 
mechanistic corroboration of why BRCA1+/- cells 
exhibit hypersensitivity to Olaparib and radiation 
compared to normal cells and those cells derived from 
BRCA2 carriers, the reasons for this reduction in 
BRCA1 protein levels is not known. However, 
off-target effects have been observed with PARP1 
inhibitors leading to the suppression of a number of 
kinases including Chk1a and ATR leading to 
replication stress, collapsed replication forks and a 
potential failure to recruit BRCA1 protein to sites of 
DNA damage during HR [33]. 
Finally, using imaging flow cytometry we have 
been able to demonstrate that the hypersensitivity of 
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the BRCA1+/− carrier cells to radiation and Olaparib is 
due to increased levels of apoptosis. This finding 
supports the observations of other investigators who 
similarly show elevated rates of apoptosis following 
Olaparib exposure in BRCA1-/- negative breast cancer 
cells [34]. 
In conclusion, the use of PARP1 inhibitors in the 
treatment of BRCA1-related cancers will no doubt 
gain momentum and moreover combinatorial treatm-
ents being evaluated and applied in clinical practice 
will expand. This investigation and our previous 
publications serve to highlight the potential problems 
of increased NTT in these scenarios. 
Competing Interests 
The authors have declared that no competing 
interest exists. 
References 
1. Michels J, Vitale I, Saparbaev M, et al. Predictive biomarkers for cancer 
therapy with PARP inhibitors. Oncogene. 2014; 33(30):3894-07. 
2. McGlynn P, Lloyd B. Recombinational repair and restart of damaged 
replication forks. Nat Rev Mol Cell Biol. 2002; 3(11):859-70. 
3. Rouleau M, Patel A, Hendzel MJ, et al. PARP inhibition: PARP1 and beyond. 
Nat Rev Cancer. 2010; 10:293-301.  
4. Benafif S, Hall M. An update on PARP inhibitors for the treatment of cancer. 
Onco Targets Ther. 2015; 8:519-28. 
5. Yoshida K, Miki Y. Role of BRCA1 and BRCA2 as regulators of DNA repair, 
transcription, and cell cycle in response to DNA damage. Cancer Sci. 2004; 
95:866-71. 
6. Mao Z, Bozzella M, Seluanov A, et al. DNA repair by nonhomologous end 
joining and homologous recombination during cell cycle in human cells. Cell 
Cycle. 2008; 7(18):2902-06. 
7. Roy R, Chun J, Powell SN. BRCA1 and BRCA2: different roles in a common 
pathway of genome protection. Nat Rev Cancer. 2012; 12:68-78. 
8. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient 
tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005; 
434:913-17. 
9. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA 
mutant cells as a therapeutic strategy. Nature. 2005; 434:917-21. 
10. Helleday T. The underlying mechanism for the PARP and BRCA synthetic 
lethality: clearing up the misunderstandings. Mol Oncol. 2011; 5:387-93. 
11. Liu Y, West SC. Distinct functions of BRCA1 and BRCA2 in double-strand 
break repair. Breast Cancer Res. 2002; 4(1):9-13. 
12. Lawrence TS, Ten Haken RK, Giaccia A. Principles of radiation oncology. In: 
DeVita VT Jr, Lawrence TS, Rosenberg SA, editors. Cancer: principles and 
practice of oncology. Philadelphia: Lippincott Williams and Wilkins; 2008: 
307-36. 
13. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology 
Group (RTOG) and the European Organization for Research and Treatment of 
Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995; 31(5):1341-46. 
14. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: Development of a 
comprehensive grading system for the adverse effects of cancer treatment. 
Semin Radiat Oncol. 2003; 13(3):176-81. 
15. Lavin MF, Shiloh Y. The genetic defect in Ataxia-telangiectasia. Annu Rev 
Immunol. 1997; 15:177-202. 
16. Nicolas N, Moshous D, Cavazzana-Calvo M, et al. A human severe combined 
immunodeficiency (SCID) condition with increased sensitivity to ionizing 
radiations and impaired V(D)J rearrangements defines a new DNA 
recombination/repair deficiency. J Exp Med. 1998; 188(4):627-34. 
17. Abbaszadeh F, Clingen PH, Arlett CF, et al. A novel splice variant of the 
DNA-PKcs gene is associated with clinical and cellular radiosensitivity in a 
patient with Xeroderma pigmentosum. J Med Genet. 2010; 47(3):176-81. 
18. Buchholz TA, Wu X, Hussain A, et al. Evidence of haplotype insufficiency in 
human cells containing a germline mutation on BRCA1 or BRCA2. Int J Cancer. 
2002; 97:557-61. 
19. Leong T, Whitty J, Keilar M, et al. Mutation analysis of BRCA1 and BRCA2 
cancer predisposition genes in radiation hypersensitive cancer patients. Int J 
Radiat Oncol Biol Phys. 2000; 48(4):959-65. 
20. Bourton EC, Foster HA, Plowman PN, et al. Hypersensitivity of BRCA1 
heterozygote lymphoblastoid cells to gamma radiation and PARP inhibitors. J 
Genet Syndr Gene Ther. 2013; 4(5). doi: 10.4172/2157-7412.1000146. 
21. Bourton EC, Plowman PN, Harvey AJ, et al. The PARP-1 inhibitor Olaparib 
causes retention of γ-H2AX foci in BRCA1 heterozygote cells following 
exposure to gamma radiation. J Cancer Ther. 2013; 4:44-52. 
22. Underhill C, Toulmonde M, Bonnefoi H. A review of PARP inhibitors: from 
bench to bedside. Ann Oncol. 2010; 22(2):268-79. 
23. Bourton EC, Plowman PN, Adam Zahir S, et al. Multispectral imaging flow 
cytometry reveals distinct frequencies of γ-H2AX foci induction in DNA 
double strand break repair defective human cell lines. Cytometry A. 2012; 
81A:130-37.  
24. Weinberg RA. The rational treatment of cancer. In: Weinberg RA, editor. The 
biology of cancer. New York: Garland Science; 2013: 797-876. 
25. Delaney G, Jacob S, Featherstone C, et al. The role of radiotherapy in cancer 
treatment: estimating optimal utilization from a review of evidence-based 
clinical guidelines. Cancer. 2005; 104(6):1129-37. 
26. Bourton EC, Plowman PN, Smith D, et al. Prolonged expression of the γ-H2AX 
DNA repair biomarker correlates with excess acute and chronic toxicity from 
radiotherapy treatment. Int J Cancer. 2011; 129(12):2928-34. 
27. Hoeller U, Tribius S, Kuhlmey A, et al. Increasing the rate of late toxicity by 
changing the score? A comparison of RTOG/EORTC and LENTA/SOMA 
scores. Int J Radiat Oncol Biol Phys. 2003; 55:1013-18.  
28. Valdiglesias V, Giunta S, Fenech M, et al. γ-H2AX as a marker of DNA double 
strand breaks and genomic instability in human population studies. Mutat 
Res. 2013; 753:24-40. 
29. Malkin D. Li Fraumeni syndrome. Genes Cancer. 2011; 2(4):475-484. 
30. Parris CN, Adam Zahir S, Al-Ali H, et al. Enhanced γ-H2AX DNA damage foci 
detection using multimagnification and extended depth of field in imaging 
flow cytometry. Cytometry A. 2015; 87(8):717-23. doi: 10.1002/cyto.a.22697. 
31. Ulus-Senguloglu G, Arlett CF, Plowman PN, et al. Elevated expression of 
artemis in human fibroblast cells is associated with cellular radiosensitivity 
and increased apoptosis. Br J Cancer. 2012; 107(9):1506-13. 
32. Chehade R, Pettapiece-Phillips R, Salmena L et al. Reduced BRCA1 transcript 
levels in freshly isolated blood leukocytes from BRCA1 mutation carriers is 
mutation specific. Breast Cancer Res. 2016; 18:87. doi: 
10.1186/s13058-016-0739-8. 
33. Kim H, George E, Ragland RL, et al. Targeting the ATR/CHK1 axis with 
PARP inhibition results in tumor regression in BRCA-mutant ovarian cancer 
models. Clin Cancer Res. 2016 Dec 19. doi: 10.1158/1078-0432.CCR-16-2273. 
34. Shi Y, Zhou F, Jiang F. PARP inhibitor reduces proliferation and increases 
apoptosis in breast cancer cells. Chin J Cancer Res. 2014; 26(2):142-47. 
 
